Conditions: Hodgkin Disease Lymphoma, Non-Hodgkin
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 50
Healthy volunteers: no

Brief summary:
Phase II study is being conducted to confirm the safety and efficacy of high-dose Melphalan HCl for Injection (Propylene Glycol-Free) when included in the BEAM regimen for myeloablative conditioning in lymphoma patients undergoing ASCT

Detailed description:

Arms:
arm 1: * Day -7, carmustine intravenous (IV) infusion
* Days -6, -5, -4, and -3, etoposide and cytarabine (IV) infusions twice a day
* Day -2, melphalan HCl (propylene glycol-free)(IV) infusion
* Day 0, stem cell transplant.

Interventions: intervention 1: Carmustine intervention 2: Etoposide phosphate intervention 3: Cytarabine intervention 4: Melphalan HCl (propylene glycol-free)
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None

Protocol document: